AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMUTEP LTD

0.290

+0.0103.57%

Volume:1.10M

Turnover:317.41K

Market Cap:422.12M

PE:-8.82

High:0.295

Open:0.280

Low:0.280

Close:0.280

Loading ...

Overview Company News Filings

Immutep Autoimmune Disease Trial Moves to Dose Escalation Phase

MT Newswires Live

Immutep Ltd - Further Updates After Data Collection and Analysis

THOMSON REUTERS

Immutep Completes Patient Enrolment in Randomised Phase Ii of Aipac-003 Trial in Metastatic Breast Cancer

THOMSON REUTERS

Immutep Completes Patient Enrolment in Metastatic Breast Cancer Study

MT Newswires Live

BRIEF-IMMUTEP Ltd Got EUR 2.2 Million Research And Development Tax Incentive Payment In Cash From French Government

Immutep Ltd: Got EUR 2.2 Mln R&D Tax Incentive Payment in Cash From French Government

THOMSON REUTERS

Immutep snaffles A$3.6M from French government for R&D

The Market Herald

Immutep Receives AU$3.6 Million Tax Rebate from French Government

MT Newswires Live

4 ASX healthcare stocks having a cracking run on Friday

The 7 biotech stocks (and their trials) these experts are watching right now

Immutep: Efti With Msd's Keytruda Leads to Positive Efficacy With Favourable Safety in First Line Head and Neck Cancer

THOMSON REUTERS

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

ASX Market Update: Aussie Index on the cusp of record as Real Estate stocks take the lead | September 16, 2024

The Market Herald

Why Cettire, Immutep, Paladin Energy, and Westgold shares are sinking today

Stocks of the Hour: Immutep, Lepidico, Mithril Silver and Gold

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/IMM.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMM.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.29,"timestamp":1741583520000,"preClose":0.28,"halted":0,"volume":1100242,"delay":0,"changeRate":0.035714,"change":0.01,"floatShares":1251930614,"shares":1455589575,"eps":-0.032898,"lyrEps":-0.035565,"pbRate":2.45,"amount":317406,"amplitude":0.053571,"volumeRatio":0.17495813934303367,"dividePrice":0,"prevYearClose":0.365,"fiveDayClose":0.305,"twentyDayClose":0.32},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1251930614,"roa":"-20.35%","roe":"-30.45%","lyrEps":-0.035565,"volumeRatio":0.17495813934303367,"shares":1455589575,"dividePrice":0,"high":0.295,"amplitude":0.053571,"preClose":0.28,"low":0.28,"week52Low":0.23,"pbRate":"2.45","psRate":"86.52","week52High":0.46,"institutionHeld":0,"latestPrice":0.29,"eps":-0.032898,"divideRate":0,"volume":1100242,"delay":0,"ttmEps":-0.032898,"open":0.28,"prevYearClose":0.365,"prevWeekClose":0.28,"prevMonthClose":0.31,"prevQuarterClose":0.365,"fiveDayClose":0.305,"twentyDayClose":0.32,"sixtyDayClose":0.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:16,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2476131678","title":"Immutep Autoimmune Disease Trial Moves to Dose Escalation Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2476131678","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476131678?lang=en_us&edition=fundamental","pubTime":"2024-10-17 10:49","pubTimestamp":1729133387,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) reported progress in its study evaluating the effectiveness of IMP761 in treating autoimmune diseases, with the trial now moving to the Part B dose escalation phase, according to a T","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","IMM.AU","BK7508","AUD","BK7067"],"gpt_icon":0},{"id":"2472969472","title":"Immutep Ltd - Further Updates After Data Collection and Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2472969472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472969472?lang=en_us&edition=fundamental","pubTime":"2024-10-03 20:00","pubTimestamp":1727956801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241003:nTUA9LLTSG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2472694440","title":"Immutep Completes Patient Enrolment in Randomised Phase Ii of Aipac-003 Trial in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2472694440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472694440?lang=en_us&edition=fundamental","pubTime":"2024-10-03 20:00","pubTimestamp":1727956801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241003:nTUA9LLTSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2472463167","title":"Immutep Completes Patient Enrolment in Metastatic Breast Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2472463167","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472463167?lang=en_us&edition=fundamental","pubTime":"2024-10-03 10:33","pubTimestamp":1727922794,"startTime":"0","endTime":"0","summary":"Biotech company Immutep  completed patient enrolment in the phase II portion of the AIPAC-003 clinical trial in metastatic breast cancer, according to a Thursday filing with the Australian Securities Exchange.A total of 65 patients will be randomized to receive 30-milligram or 90-milligram doses of eftilagimod alpha in combination with paclitaxel to determine the optimal biological dose in line with the Food and Drug Administration's Project Optimus initiative, the filing said.Immutep shares slid 2% in midday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2469254463","title":"BRIEF-IMMUTEP Ltd Got EUR 2.2 Million Research And Development Tax Incentive Payment In Cash From French Government","url":"https://stock-news.laohu8.com/highlight/detail?id=2469254463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469254463?lang=en_us&edition=fundamental","pubTime":"2024-09-24 18:10","pubTimestamp":1727172633,"startTime":"0","endTime":"0","summary":"Sept 24 (Reuters) - Immutep Ltd   :   * IMMUTEP LTD: GOT EUR 2.2 MILLION RESEARCH AND DEVELOPMENT TAX INCENTIVE PAYMENT IN CASH FROM FRENCH GOVERNMENTFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2469929463","title":"Immutep Ltd: Got EUR 2.2 Mln R&D Tax Incentive Payment in Cash From French Government","url":"https://stock-news.laohu8.com/highlight/detail?id=2469929463","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469929463?lang=en_us&edition=fundamental","pubTime":"2024-09-24 18:08","pubTimestamp":1727172539,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240924:nFWN3L6072:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2469846881","title":"Immutep snaffles A$3.6M from French government for R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2469846881","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469846881?lang=en_us&edition=fundamental","pubTime":"2024-09-24 08:11","pubTimestamp":1727136660,"startTime":"0","endTime":"0","summary":"Biotech company Immutep Ltd  has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates.The incentive – worth 2,194,918 – was provided under the government’s Crédit d’Impt Recherche scheme  – for which Immutep is eligible due to activities carried out at its laboratory in France.Under the scheme, companies can be reimbursed 30% of their eligible expenditure on research and development activities. In this case, Immutep will be plugging it into global clinical development of candidates eftilagimod alpha and IMP761.These are candidates central to the company’s mission to develop Lymphocyte Activation Gene -3 immunotherapies for cancer and autoimmune diseases.Eftilagimod alpha is Immutep’s proprietary soluble LAG-3 clinical stage candidate which is a first-in-class antigen presenting cell  activator for the treatment of cancer, while IMP761 is a first-in-class immunosuppressive agonist antibody to LAG-3.Immutep","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/immutep-snaffles-a3-6m-from-french-government-for-rd-2024-09-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LU2237443622.USD","LU2237443978.SGD","CIR","LU0157215616.USD","LU2237443382.USD","APC","IMM.AU","LU2237443549.SGD","LU0077335932.USD","LU1366333091.USD","BK7095","APC.AU","BK7067","BK7508","BK4161"],"gpt_icon":0},{"id":"2469170680","title":"Immutep Receives AU$3.6 Million Tax Rebate from French Government","url":"https://stock-news.laohu8.com/highlight/detail?id=2469170680","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469170680?lang=en_us&edition=fundamental","pubTime":"2024-09-24 07:35","pubTimestamp":1727134537,"startTime":"0","endTime":"0","summary":"Immutep  received roughly AU$3.6 million in research and development-related tax incentives from the French government, according to a Tuesday filing with the Australian bourse.The ASX-listed biotechnology company received the payment through its subsidiary, Immutep SAS. Under the French government's Research Tax Credit scheme, French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure, the filing stated.Immutep said it will use the funds for the global clinical development of eftilagimod alpha and IMP761.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2468666370","title":"4 ASX healthcare stocks having a cracking run on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2468666370","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468666370?lang=en_us&edition=fundamental","pubTime":"2024-09-20 11:20","pubTimestamp":1726802421,"startTime":"0","endTime":"0","summary":"The Australian share market is ending the week on a positive note. In afternoon trade, the All Ordinaries  index is up 0.45%. Four ASX healthcare stocks that are outperforming by some distance and making their shareholders smile today are listed below. Let's see why they are having a cracking run on Friday. What's happening?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/09/20/4-asx-healthcare-stocks-having-a-cracking-run-on-friday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CU6.AU","BK7508","BK7067","IMM.AU","NEU.AU","TLX.AU","BK7096","XAO.AU"],"gpt_icon":1},{"id":"2468763713","title":"The 7 biotech stocks (and their trials) these experts are watching right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2468763713","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468763713?lang=en_us&edition=fundamental","pubTime":"2024-09-20 07:19","pubTimestamp":1726787992,"startTime":"0","endTime":"0","summary":"Somewhere in the world right now, a scientist could be plotting a game-changing molecular treatment for the world’s most challenging illnesses. Or such a treatment could be in trial right now. Such is the extraordinary nature and pace of advances in biotechnology today.Layman investors might well be aware of the importance of trials as a process to get products or treatments to commercial shelves, but not necessarily the finer details or even what trials the experts are watching.The world of biotechnology and clinical trials is not always easy to interpret and in light of that, I spoke to two experts to discuss some of the clinical trials they are monitoring in Australia and globally and why, along with their recommendations for other investors.Dr Bianca Ogden, Portfolio Manager – Health Care Strategies, Platinum Asset Management. Hashan De Silva, Founder and Managing Partner, KP Rx. There are typically three phases of trials, with the first typically taken on healthy volunteers as a s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-7-biotech-stocks-and-their-trials-these-experts-are-watching-right-now","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-7-biotech-stocks-and-their-trials-these-experts-are-watching-right-now","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["NEU.AU","BK7067","BK7096","OPT.AU","XKO.AU","BCYC","CNTA","TLX.AU","XJO.AU","BK4139","BK4539","BK4535","XAO.AU","IMM.AU","SNT.AU","BK7508"],"gpt_icon":0},{"id":"2467147308","title":"Immutep: Efti With Msd's Keytruda Leads to Positive Efficacy With Favourable Safety in First Line Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2467147308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467147308?lang=en_us&edition=fundamental","pubTime":"2024-09-16 20:12","pubTimestamp":1726488747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240916:nFWN3KY0C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"2467814662","title":"Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2467814662","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467814662?lang=en_us&edition=fundamental","pubTime":"2024-09-16 20:00","pubTimestamp":1726488000,"startTime":"0","endTime":"0","summary":"Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024. In patients with any PD-L1 expression , efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% ORR  versus 18.5% ORR for KEYTRUDA. Efti in combination with KEYTRUDA led to a high durability of response of 17.5 months in patients with any PD-L1 expression and combination continues to have favourable safety profile. Statistically significant increase in absolute lymphocyte count biomarker seen in the efti in combination with KEYTRUDA arm shows efti’s biological activity in a randomised setting. Dr. Frédéric Triebel, CSO of Immutep, said “Through multiple clinical trials, we see the promise of efti to not only improve cancer patients’ clinical responses to immune checkpoint inhibitors, but also to expand patient populations who respond to them including patients with negati","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-efti-combination-msd-keytruda-120000427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0265550946.USD","IE00BSNM7G36.USD","BK4198","LU0320765489.SGD","IE00B2B36J28.USD","LU0234572021.USD","LU0861579265.USD","LU1066053197.SGD","LU0965509010.AUD","IE00BBT3K403.USD","IE00BN8TJ469.HKD","LU1291159041.SGD","LU1917777945.USD","IE000M9KFDE8.USD","IMM.AU","LU1093756168.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0203347892.USD","LU1066051225.USD","MRK","LU1116320901.HKD","LU0965509283.SGD","BK4516","BK4588","LU0965508806.USD","LU0211331839.USD","LU1934455863.HKD","IMMP","ALC","LU0106261372.USD","LU1093756325.SGD","LU0266013472.USD","IE0009355771.USD","LU1934455194.USD","IE00B1BXHZ80.USD","IE0002141913.USD","LU0122379950.USD","BK4585","IE00BLSP4452.SGD","LU1585245621.USD","IE00B4R5TH58.HKD","BK4139","BK4534","LU0208291251.USD","LU1061106388.HKD","LU0006306889.USD","BK4007","LU1037948541.HKD","LU0238689110.USD","LU0965509101.SGD"],"gpt_icon":0},{"id":"2467389852","title":"ASX Market Update: Aussie Index on the cusp of record as Real Estate stocks take the lead | September 16, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2467389852","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467389852?lang=en_us&edition=fundamental","pubTime":"2024-09-16 11:21","pubTimestamp":1726456860,"startTime":"0","endTime":"0","summary":"Good afternoon. The ASX200 has been up 0.42% at 8,134 points. The local bourse is very close to breaking its record of 8,148 set in August.The Aussie market has so far shrugged of a second assassination attempt on former President Trump in the United States, but all eyes are on Wall Street’s reaction. At 1pm Sydney time, the S&P 500 and Nasdaq futures are flat.The Real Estate sector has been up more than 1%, followed by Telecommunication up around point eight of a percent. Health Care has been down point six of a percent and Utilities has lost around point three of a percent.Raiden Resources has been up 11.3% after chalking up a second works approval.Immutep  has been down 10% on release of positive efficacy and safety results from its Phase 2b drug trial. The first-line treatment of recurrent or metastatic head and neck cancer is being evaluated, but the results have failed to inspire investors.Encounter Resources has been up 6.5% after unveiling a fresh set of niobium assays from rec","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-aussie-index-on-the-cusp-of-record-as-real-estate-stocks-take-the-lead-september-16-2024-2024-09-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","BK7508","BK7095","ENR.AU","IMM.AU","RDN.AU"],"gpt_icon":0},{"id":"2467686899","title":"Why Cettire, Immutep, Paladin Energy, and Westgold shares are sinking today","url":"https://stock-news.laohu8.com/highlight/detail?id=2467686899","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467686899?lang=en_us&edition=fundamental","pubTime":"2024-09-16 10:26","pubTimestamp":1726453564,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is continuing its positive run and pushing higher on Monday. In afternoon trade, the benchmark index is up 0.45% to 8,137.4 points. Four ASX shares that have failed to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/09/16/why-cettire-immutep-paladin-energy-and-westgold-shares-are-sinking-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IMM.AU","PDN.AU","BK7049","00495","BK7083","BK7067","BK7506","BK7508","CTT.AU","WGX.AU","XJO.AU","BK1229","BK1258","BK7021","BK7104","BK7509"],"gpt_icon":0},{"id":"2467891821","title":"Stocks of the Hour: Immutep, Lepidico, Mithril Silver and Gold","url":"https://stock-news.laohu8.com/highlight/detail?id=2467891821","media":"ShareCafe","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467891821?lang=en_us&edition=fundamental","pubTime":"2024-09-16 10:03","pubTimestamp":1726452183,"startTime":"0","endTime":"0","summary":"A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Lepidico (ASX:LPD) and Mithril Silver and Gold (ASX:MTH).","market":"us","thumbnail":"https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/435d82edd8c0d0bfbf6e40776d007e57ec77251d.jpg","type":0,"news_type":0,"thumbnails":["https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/435d82edd8c0d0bfbf6e40776d007e57ec77251d.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.sharecafe.com.au/2024/09/16/stocks-of-the-hour-immutep-lepidico-mithril-silver-and-gold/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","LPD.AU","MTH.AU","IMM.AU","BK7095","BK7508","BK7504"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":4,"totalSize":63}]}}